SXI Life Sciences
7.474,53
PKT
-41,24
PKT
-0,55
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
27.04.05 | Roche Buy | Helvea | |
27.04.05 | Roche Kaufen | Hamburger Sparkasse | |
26.04.05 | Straumann Outperform | Goldman Sachs | |
26.04.05 | Novartis Kaufen | Hamburger Sparkasse | |
25.04.05 | Straumann Sector Perform | Vontobel | |
22.04.05 | Novartis Hold | SEB | |
22.04.05 | Novartis Outperform | Goldman Sachs | |
22.04.05 | Novartis Overweight | Lehman Brothers | |
27.04.05 | Novartis Kaufen | NATIONAL-BANK | |
21.04.05 | Roche Outperform | Goldman Sachs | |
21.04.05 | Novartis Buy | Merrill Lynch | |
21.04.05 | Roche Sector Outperform | Vontobel | |
21.04.05 | Novartis Akkumulieren | Independent Research | |
21.04.05 | Novartis Neutral | Sarasin Research | |
22.04.05 | Novartis Kaufen | Helaba Trust | |
20.04.05 | Roche Buy | Sarasin Research | |
20.04.05 | Roche Outperform | Goldman Sachs | |
20.04.05 | Roche Overweight | JP Morgan | |
20.04.05 | Roche Equal weight | Lehman Brothers | |
19.04.05 | BB Biotech Kaufen | Hamburger Sparkasse | |
19.04.05 | Novartis Buy | Merrill Lynch | |
19.04.05 | Roche Halten | Helaba Trust | |
21.04.05 | Novartis Underperform | Credit Suisse First Boston | |
19.04.05 | Roche Akkumulieren | Independent Research | |
19.04.05 | Roche Buy | Sarasin Research | |
18.04.05 | Novartis Outperform | Goldman Sachs | |
19.04.05 | Roche Equal weight | Lehman Brothers | |
19.04.05 | Novartis Neutral | JP Morgan | |
19.04.05 | Roche Overweight | JP Morgan | |
15.04.05 | Novartis Kaufen | Helaba Trust | |
15.04.05 | Roche In-Line | Goldman Sachs | |
18.04.05 | Novartis Neutral | Sarasin Research | |
15.04.05 | Roche In-Line | Goldman Sachs | |
18.04.05 | Novartis Neutral | HypoVereinsbank | |
18.04.05 | Roche Buy | Sarasin Research | |
18.04.05 | Roche Buy | Helvea | |
18.04.05 | Roche Outperform | HypoVereinsbank | |
14.04.05 | Novartis Reduce | UBS | |
14.04.05 | Novartis Reduce | UBS | |
14.04.05 | Roche Halten | Helaba Trust |